[On the efficacy of carbocromen in the treatment of myocardial infarction (author's transl)].

Comparative clinical trials on 100 infarcted patients have demonstrated the therapeutic superiority of 3-(2-diethylamino-ethyl)-4-methyl-7-(carbethoxy-methoxy)-2-oxo-1,2-chromene-hydrochloride (carbocromen; Intensain). 50 patients were treated eith carbocromen and 50 with papaverine as controls. Overall improvement under the influence of carbocromen was observed. Carbocromen eliminates ischemic pain, in contrast to papaverine, without any change in blood pressure even in the case of i.v. administration. The typical pathological changes in the ECG were normalized more rapidly and disturbances in the cardiac rhythm have been observed in only one case in the carbocromen group, while in the papaverine group extrasystolic arrhythmias, paroxysmal fibrillation and disturbances in atrioentricular conduction often occurred. Acute cardiovascular insufficiency in carbocromen treated patients was observed in only one case, but in 6 patients of the papaverine group. Out of the patients who displayed the same unfavorable prognosis, 6 patients died of the papaverine group and only one of the carbocromen group. By all patients carbocromen was well tolerated and there were no side-effects. Due to the results of our investigations the application of carbocromen in the treatment and prophylaxis of myocardial infarction is of advantage.